NF2 and meningioma: That no difference is seen in either ipsi- or contralateral hearing loss progression in this patient population, compared to patients with unilateral VS only, is reassuring that they are not hiding an occult NF2 mutation, and supports use of current guidelines for limiting NF2 diagnosis to only patients with either bilateral VS, ≥3 schwannomas or meningiomas, or unilateral VS plus known family history.